Drug intelligence / Profile preview

donepezil + rasagiline

Development stage: Preclinical
Lead developer: Eisai
Modality: Small Molecules
Administration: Oral

Overview

A combination of donepezil, an acetylcholinesterase inhibitor, and rasagiline, a selective and irreversible monoamine oxidase B (MAO-B) inhibitor. Donepezil works by inhibiting the breakdown of acetylcholine in the brain, thereby increasing cholinergic transmission, which may help relieve symptoms of Alzheimer's disease. Rasagiline works by inhibiting MAO-B, which increases dopamine levels in the brain, potentially helping with Parkinson's disease symptoms. When combined, these medications may have a drug interaction that increases the risk of CNS depression.

Targets

MAOB (Monoamine oxidase B)Acetylcholinesterase

Beyond the preview

Go deeper on donepezil + rasagiline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on donepezil + rasagiline.

Explore the full profile